Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets remain afloat
Mon, 30 Jun 01:30 pm

The Indian stock markets continued to trade higher during the previous two hours of trade led by continuous buying activity among the index heavy weights. All sectoral indices are trading firm, led by heavy buying from the power and capital goods sectors.

The BSE-Sensex is trading up by 281 points and the NSE-Nifty is trading up by 89 points. The BSE Mid Cap index is trading up 1.6% and the BSE Small Cap index is trading up 1.6% today. The rupee is trading at 60.09 to the US dollar.

Almost all power stocks are trading firm today led by Jaiprakash Power and JSW Energy. As per a leading business daily, NTPC has informed the coal ministry that it plans to commence coal production at its two captive mines at Chhattisgarh by June 2016. However, it's third mine in the state will become operational only by 2038. Earlier, due to issue of development within the stipulated time frame these three blocks were forfeited from the company, which were later returned. The delay was also due to lack of support from the state government. Now the company has informed to the ministry that it has completed all milestones like mining plan, its closure plan and environment and forest clearance. But for one of the mines the forest clearance and land acquisition is still under way. NTPC is trading up 1.4%.

Indian Pharma stocks are trading mixed. Elder Pharma and Ranbaxy are trading firm whereas Indoco Remedies is trading weak. As per a leading business daily, Dr Reddy's has filed its FY14 annual report with the US SEC (Securities and Exchange Commission). The company annual report provided key information with respect to its spending on expansion and building capacity. It will finance most of its expansion projects through operating cash flow or through the use of investment & cash. The company management expects most of its projects to get completed by FY16. This provides relief as its spending is going to ease after FY16. For instance, it has used Rs 14.5 bn and Rs 18.8 bn in its cash flow from investment during FY12 and FY13 respectively. The stock is trading higher by 1.5% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets remain afloat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.